Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018		Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 23,587		$ 36,838
Marketable equity securities	7,154		1,337
Trade accounts and grants receivable, net	767		780
Landlord receivable	840
Receivables from affiliates, net	2,112		2,266
Prepaid expenses and other current assets	1,898		1,402
Total current assets	36,358		42,623
NONCURRENT ASSETS
Property and equipment, net	5,835		5,533
Deposits and other long-term assets	505		1,018
Promissory note from Juvenescence (Note 3)	22,104
Intangible assets, net	3,125	[1]	6,900
TOTAL ASSETS	101,660		173,241
CURRENT LIABILITIES
Accounts payable and accrued liabilities	6,463	[1]	5,718
Capital lease and lease liability, current portion	237		212
Promissory notes, current portion	70		152
Deferred license and subscription revenues			488
Deferred grant revenue	42		309
Total current liabilities	6,812		6,879
LONG-TERM LIABILITIES
Deferred rent liabilities, net of current portion	244		105
Lease liability, net of current portion	1,854		1,019
Capital lease, net of current portion	104		132
Promissory notes, net of current portion			18
Liability classified warrants and other long-term liabilities	400		825
TOTAL LIABILITIES	9,414		8,978
Commitments and contingencies (Note 15)
SHAREHOLDERS' EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of December 31, 2018 and 2017, respectively
Common stock, no par value, authorized 250,000 shares; 127,136 and 126,866 shares issued and outstanding as of December 31, 2018 and 2017, respectively	354,270		378,487
Accumulated other comprehensive income	1,426		451
Accumulated deficit	(261,856)		(216,297)
BioTime, Inc. shareholders' equity	93,840		162,641
Noncontrolling interest (deficit)	(1,594)		1,622
Total shareholders' equity	92,246		164,263
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	101,660		173,241
OncoCyte Corporation [Member]
NONCURRENT ASSETS
Equity method investment at fair value	20,250		68,235
SHAREHOLDERS' EQUITY
Common stock, no par value, authorized 250,000 shares; 127,136 and 126,866 shares issued and outstanding as of December 31, 2018 and 2017, respectively	20,300
Asterias Biotherapeutics [Member]
NONCURRENT ASSETS
Equity method investment at fair value	$ 13,483		$ 48,932

[1] Reflects the effect of the AgeX Deconsolidation.